Fort Collins-based VetDC posts positive results for canine cancer drug
FORT COLLINS — VetDC Inc. announced Tuesday that the Fort Collins-based company has concluded a field study that yielded promising results for its drug Tanovea that is intended to treat lymphoma in dogs.
While lymphoma is widely considered one of the most common cancers seen in dogs and cats, there are no FDA-approved lymphoma treatments in the United States. The current standard of care for lymphoma treatment is a multidrug chemotherapy regimen —referred to as CHOP — which typically requires 12 to 16 visits.
The veterinary cancer therapeutics company said its drug Tanovea, in combination with doxorubicin — a commonly used generic chemotherapy agent — delivered an 81 percent response rate when tested on 54 dogs with lymphoma.
SPONSORED CONTENT
Federal District Court Rules Corporate Transparency Act Unconstitutional . . . But Most Small Businesses Must Still Comply
Lyons Gaddis Real Estate and Business Attorney Cameron Grant shares important details of the Corporate Transparency Act (CTA).
The Tanovea/doxorubicin combination was found to be generally safe and well tolerated in this study, with gastrointestinal and hematologic adverse effects being the most common events reported.
“We are encouraged by the results seen in this study, and we are working closely with the veterinary oncology community and regulatory authorities to introduce this important new advancement for the benefit of dogs with lymphoma Steven Roy, VetDC’s chief executive, said in a prepared statement.
Tanovea is currently under regulatory review with the FDA Center for Veterinary Medicine and is not yet approved for commercial sale.
